The BioEconomy By Dr J R Webster Executive Director: AfricaBio

Slide1 l.jpg
1 / 43
1291 days ago, 381 views
PowerPoint PPT Presentation
The BioEconomy. Worldwide biotechnology flow. Status in Africa. Where are we in South Africa? Will we have a BioEconomy?. CURRENT TRENDS IN THE BIOTECHNOLOGY INDUSTRY. the biotechnology century. Current patterns. In 2000,biotech organizations raised US$37.2 billion through open and private financing, US $10 billion in 2001 The fruition of the

Presentation Transcript

Slide 1

The BioEconomy By Dr J R Webster Executive Director: AfricaBio

Slide 2

The BioEconomy Global biotechnology flow. Status in Africa. Where are we in South Africa? Will we have a BioEconomy?

Slide 3

CURRENT TRENDS IN THE BIOTECHNOLOGY INDUSTRY the biotechnology century Current patterns In 2000,biotech organizations raised US$37.2 billion through open and private financing, US $10 billion in 2001 The finish of the "unpleasant" draft of the arrangement of the human genome flags another time in the biotech business. This implies the biotech business has its greatest years in front of it. 4,254 biotech organizations internationally in 25 countries

Slide 4

CONTINUATION OF CURRENT TRENDS IN THE BIOTECHNOLOGY INDUSTRY Biotech organizations grow the greater part of the affirmed prescriptions in the US Biotech organizations can be categorized as one of two classifications: Product advancement e.g. Genetech, MedImmune, Qiagen Service Companies e.g. Celera,Incyte,Evotec

Slide 5

Current Trends contd . 622 open biotech organizations created $35 billion Spent $16 billion in R&D Employed 188,000 in 2001 72% of incomes produced by US organizations

Slide 6

Biotechnology organizations are at present recorded on the: Neuer Market EASDAQ Swiss New Market NASDAQ

Slide 7

Alliances Pharmaceutical industry has perceived the esteem conveyed by biotechnology to the medication improvement prepare. Biotech-pharma collusions for medication revelation have been expanding consistently from 101 cooperations between 1988 to1993 to 145 organizations together in 1997 and 1998 alone. More than 480 pharm – biotech joint efforts and 550 biotech – biotech organizations all inclusive in 2001. Organizations together in different regions – sedate conveyance, antibodies and so forth have been expanding at a comparable rate.

Slide 8

Measurements of Success in Biotechnology Financial-What happened to the Nasdaq Biotech Index The Nasdaq speaks to the most effectively exchanged biotech stocks. The record is a capitalisation-weighted file. The Nasdaq Biotech index(NBI) has expanded 437% since its commencement on Nov. 1 1993. In 2000, The NBI expanded 23% out-playing out all other Nasdaq lists.

Slide 9

Biotech Product advancement (tranquilize improvement) Matured since 1982 when r-insulin was created. Presently more than 120 endorsed biotech drugs accessible. Presently more than 300 in last period of clinical advancement in the USA alone. Biotech items now represent half of all recently affirmed prescriptions in the USA-this will increment. Organizations not utilizing biotech will pay twofold the expenses to deliver another prescription.

Slide 10

What will expand biotech item advancement? Genomics Currently 500 illness targets are utilized to grow new solutions. In 5-10 years genomics will convey 5,000-10,000 malady targets

Slide 11

g c g c g c g c g c t c g c Advanced Genomics Will Accelerate Discovery of Next Generation Products Genome Gene outline arrangement Gene expression Ag attributes Pharma characteristics c Yield t Alzheimers Drought Breast Cancer a t Disease Arthritis Stress t Stress an a t Stress CV Disease an a t Aging Oil quality an a t Disease Obesity Vision Yield Aging Maturity a t Arthritis Herbicide resistance Solving neglected needs in human wellbeing and nourishment creation

Slide 12

How does strategy influence biotech business and approach improvement? Enter development calculate USA pharmaceutical industry has been the Orphan Drug Act 1983. To defeat absence of speculation into medications to treat little quantities of patients-US allowed 7yr eliteness and different motivating forces to organizations for vagrant medications. Presently 900 vagrant medications created with 200 affirmed. Biotech organizations record 85% of utilizations for new vagrant medications. This approach has now been embraced in the EU.

Slide 13

Predictions 2010: Predictions tests for 25 hereditary conditions will be conceivable alongside mediations to lessen danger of their onset 2020: Designer drugs for diabetes, hypertension, tumor and other significant diseases will be created and endorsed for patients in light of hereditary profile, making medications more compelling 2030: Genes required in maturing will be completely described and clinical trials of medications to augment typical human life will be in progress 2040: Comprehensive genomics-based medicinal services will be the standard

Slide 14

New Advances

Slide 22

NOVEL APPLICATIONS OF BIOTECH Spider silk-gathered from protein in goats drain (slug verification vest, restorative applications) Plants as manufacturing plants for pharmaceuticals and mechanical items, (biopolymers, new oils or filaments) as biosensors, salt tolerant products (develop in ocean water) virtual plants Flowers with various examples, miniturized and longer time span of usability

Slide 23

WHAT ABOUT DEVELOPING COUNTRIES? Innovation separation will proceed unless governments contribute (see World Bank-Health Genomics Divide report) New African Initiative could be reached out to genomics Cuba has 400 biotech licenses (trading biotech immunizations) Brazil has quickly creating genomics and biotech industry India expanding interest in genomics and biotech ($85 million on genomics in next 5 years) Nigeria and South Africa contributing

Slide 24

GM Crops broad Over 30 GM Crops. Counting the accompanying: maize, wheat, soya beans, papaya, raspberries, tomatoes, canola, potatoes, peppers, cabbage, cucumber, squash, cotton, grapes, carrots and chicory. Trees, turf, blossoms

Slide 25


Slide 26

Where are we with GM crops around the world? GM edit planting all inclusive expanded by 11% in 2000 and >10% in 2001. It has backed off because of moderate improvement of new markets and absence of items with buyer advantage More creating nations are commericalising and putting resources into yield biotech China needs to be the Asian focus of brilliance Between 1997 and 1999 China endorsed 26 applications for commercialisation of GMOs, 59 for natural discharges and 73 for field trials

Slide 27

Biotechnology R&D in sub Saharan Africa

Slide 28

Status of R&D in sub-Saharan Africa Primarily second era biotechnology e.g. plant tissue culture (Ghana: cassava, yam, pineapple, cocoa,banana,etc; Nigeria:cassava,yam,banana,cowpea and so on). Hereditary building ventures went for irritation and ailment resistant crops. Crops include: sweet potato, banana, sugar stick, cassava, sorghum and maize. Different tasks incorporate improvement of atomic markers and probes.

Slide 29

Field Trials in Africa-What's the Reality? Infection safe sweet potato in Kenya, expect creepy crawly safe maize soon and potentially contagious safe banana. Being or to be tried in Egypt is GM squash, melon, cantalope, tomato, potato, sugarcane, maize, cucumber and wheat. Creepy crawly safe cotton in Zimbabwe. Few GM edit field trials in Africa and South Africa is the main nation with business GM trim however GM wares are prepared for fare to Africa.

Slide 30

Status of Biotechnology in South Africa* Over 500 biotechnology ventures spread more than seven sectors. Restorative and pharmaceutical segment pulls in the most funding; plant segment second biggest. Couple of nearby items are created, imported technology is driving commercialisation & industrial development. Half biotechnology financing is spent on hereditary modification ventures. Purchaser mindfulness is basic. * Taken from report for CSIR 1998 (Webster & Koch)

Slide 31

South Africa as a Case Study R&D for a long time Plant trials for a long time (utilizing existing arrangement) New GMO arrangement executed in * 1999 Only 4 business endorsements by end 200 1 About 110 plant biotech bunches (scholastic and research) Over 160 plant biotech extends About 45 organizations utilizing biotechnology in nourishment, sustain and fiber Public not educated; Anti-activists having an effect

Slide 32

Changes in SA status National Strategy Labeling Legislation Venture capital Bioincubator Consumer observations

Slide 33

Successful Application of Biotech gives positive discernments

Slide 34

Change in Approach of EU Purvis report has a great deal of bolster Want to be the information based focus of perfection and highlighted biotechnology Purvis report contradicts that restorative biotech gives opportunity and agbiotech gives dangers Regrets ban to GM which was not in light of logical proof EU has not authorized new GM crops since Oct. 1998 New controls mean lifting of moratorium,GM products will be planted in spring 2002 in Europe

Slide 35

Future prospects in EU New biotech technique for EU is being created AfricaBio had contribution to this in Sept 2001 Commercialization of GM yields will continue however will be ease back Different way to deal with open mindfulness proclamations by EU e.g 15yrs of GM security look into has been completed with 81 ventures and 400 groups from various orders GM edits similarly as sheltered as customary nourishments

Slide 36

What lies ahead for biotech organizations? Biotech business still toward the start of the development stage Biotech is still observed as high hazard Estimate that achievement rate for biotech business is 13% Biotech organizations established in the following 5 yrs have an opportunity to show improvement over their antecedents Biotech acquisitions will keep Partnering was Pharm/Biotech will be more Biotech/Biotech

Slide 40

What is the Bio-Based Economy? Fossil C vitality Product Non-renewable assets Conventional Process Waste Landfill or burn Renewable vitality Bio-item Renewable bio-asset Bio-Based Bio-prepare Byproduct Recycle into bio-asset Dr. J.F.Jaworski

Slide 41

Role of Biotechnology in the Bio-Based Economy (OECD) One of a few key empowering advances Biotechnology is focalizing with information innovation, science, physical science, materials and nano-innovation Bioprocesses: biotech can increment eco-productivity Bio-assets: biotech can increment